Identification and function of coactivator of estrogen receptor: ERIAP

Article

Abstract

Estrogen receptor (ER), one member of nuclear hormone receptor (NR) family, is an estrogen-dependent transcriptional factor that plays an important role in development, progression and treatment of breast cancer. Transcriptional co-factors (co-activators and co-repressors) are critical for ER to transduce hormone and metabolic signaling to target genes. A number of functional and structural studies have elucidated the precise mechanisms of co-activator interaction with the ligand-inducible activation domain in ER via one and several LXXLL motifs (where X is any amino acid) known as NR-Box. By the yeast two-hybrid system we have identified a novel ER-α interacting protein ERIAP (Estrogen Receptor Interacting and Activating Protein) which contains two consensus LXXLL motifs. ERIAP associated with ER-α in a ligand-dependent manner, as demonstrated by in vivo immunoprecipitation and in vitro GST capture assays. The two NR boxes were essential for ERIAP interaction with ER-α. Furthermore, ERIAP specifically enhanced ligand-mediated ER-α transcriptional activity in a dose-dependent fasion and increased the expression of estrogen-responsive gene pS2. Thus, our present findings indicate that ERIAP funcions as a new coactivator for ER-α transcriptional activity, which may play an important role in development and progression of breast cancer.

Keywords

estrogen receptor breast cancer new gene ERIAP 

References

  1. 1.
    Gross, R. E., Breast cancer: Risk factors, screening, and prevention, Semin Oncol. Nurs., 2000, 16: 176–184.PubMedCrossRefGoogle Scholar
  2. 2.
    Ferno, M., Borg, A., Johansson, U. et al., Estrogen and progesterone receptor analyses in more than 4000 human breast cancer samples. A study with special reference to age at diagnosis and stability of analyses, Acta Oncol., 1990, 29: 129–135.PubMedCrossRefGoogle Scholar
  3. 3.
    Dickson, R. B., Lippman, M. E., New approaches in the therapy of breast cancer—Introduction, Breast Cancer Res. Treat., 1996, 38: 1–2.PubMedCrossRefGoogle Scholar
  4. 4.
    Katzenellenbogen, B. S., Katzenellenbogen, J. A., Estrogen receptor alpha and estrogen receptor beta: Regulation by selective estrogen receptor modulators and importance in breast cancer, Breast Cancer Res., 2000, 2: 335–344.PubMedCrossRefGoogle Scholar
  5. 5.
    Russo, J., Hu, Y. F., Yang, X. et al., Developmental, cellular, and molecular basis of human breast cancer, J. Natl. Cancer Inst., 2000, 27: 17–37.Google Scholar
  6. 6.
    Beato, M., Herrlich, P., Schutz, G., Steroid hormone receptors: Many actors in search of a plot, Cell, 1995, 83: 851–857.PubMedCrossRefGoogle Scholar
  7. 7.
    Truss, M., Beato, M., Steroid hormone receptors: Interaction with deoxyribonucleic acid and transcription factors, Endocr. Rev., 1993, 14: 459–479.PubMedGoogle Scholar
  8. 8.
    Tsai, M. J., O’Malley, B. W., Molecular mechanisms of action of steroid/thyroid receptor superfamily members, Annu. Rev. Biochem., 1994, 63: 451–486.PubMedCrossRefGoogle Scholar
  9. 9.
    Mangelsdorf, D. J., Thummel, C., Beato, M. et al., The nuclear receptor superfamily: The second decade, Cell, 1995, 83: 835–839.PubMedCrossRefGoogle Scholar
  10. 10.
    Kumar, V., Green, S., Stack, G. et al., Functional domains of the human estrogen receptor, Cell, 1987, 51: 941–951.PubMedCrossRefGoogle Scholar
  11. 11.
    Gronemeyer, H., Transcription activation by estrogen and progesterone receptors, Annu. Rev. Genet., 1991, 25: 89–123.PubMedCrossRefGoogle Scholar
  12. 12.
    Smith, C. L., Cross-talk between peptide growth factor and estrogen receptor signaling pathways, Biol. Reprod., 1998, 58: 627–632.PubMedCrossRefGoogle Scholar
  13. 13.
    Tora, L., White, J., Brou, C. et al., The human estrogen receptor has two independent nonacidic transcriptional activation functions, Cell, 1989, 59: 477–487.PubMedCrossRefGoogle Scholar
  14. 14.
    Webster, N. J., Green, S., Tasset, D. et al., The transcription activation function located in the hormone-binding domain of the human oestrogen receptor is not encoded by a single exon, EMBO J., 1989, 8: 1441–1446.PubMedGoogle Scholar
  15. 15.
    Horwitz, K. B., Jackson, T. A., Bain, D. L. et al., Nuclear receptor coactivators and corepressors, Mol. Endocrinol., 1996, 10: 1167–1177.PubMedCrossRefGoogle Scholar
  16. 16.
    McKenna, N., Lanz, R., O’Malley, B., Nuclear receptor coregulators: Cellular and molecular biology, Endocr. Rev., 1999, 20:321–344.PubMedCrossRefGoogle Scholar
  17. 17.
    Glass, C. K., Rosenfeld, M. G., The coregulator exchange in transcriptional functions of nuclear receptors, Genes Dev., 2000, 14: 121–141.PubMedGoogle Scholar
  18. 18.
    Heery, D. M., Kalkhoven, E., Hoare, S. et al., A signature motif in transcriptional co-activators mediates binding to nuclear receptors, Nature, 1997, 387: 733–736.PubMedCrossRefGoogle Scholar
  19. 19.
    He, B., Wilson, E. M., Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs, Mol. Cell Biol., 2003, 23: 2135–2150.PubMedCrossRefGoogle Scholar
  20. 20.
    Gaughan, L., Brady, M. E., Cook, S. et al., Tip60 is a co-activator specific for class I nuclear hormone receptors, J. Biol. Chem., 2001, 276: 46841–46848.PubMedCrossRefGoogle Scholar
  21. 21.
    Wong, C. W., Komm, B., Cheskis, B. J., Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators, ER selective ligands, Biochemistry, 2001, 40: 6756–6765.Google Scholar
  22. 22.
    Zhang, H., Thomsen, J. S., Johansson, L. et al., DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors, J. Biol. Chem., 2000, 275: 39855–39859.PubMedCrossRefGoogle Scholar
  23. 23.
    Warnmark, A., Almlof, T., Leers, J. et al., Differential recruitment of the mammalian mediator subunit TRAP220 by estrogen receptors ERalpha and ERbeta, J. Biol. Chem., 2001, 276: 23397–23404.PubMedCrossRefGoogle Scholar
  24. 24.
    Gee, A. C., Carlson, K. E., Martini, P. G. et al., Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor, Mol. Endocrinol., 1999, 13: 1912–1923.PubMedCrossRefGoogle Scholar
  25. 25.
    Schaufele, F., Regulation of estrogen receptor activation of the prolactin enhancer/promoter by antagonistic activation function-2-interacting proteins, Mol. Endocrinol., 1999, 13: 935–945.PubMedCrossRefGoogle Scholar
  26. 26.
    Kalkhoven, E., Valentine, J. E., Heery, D. M. et al., Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor, EMBO J., 1998, 17: 232–243.PubMedCrossRefGoogle Scholar
  27. 27.
    McInerney, E. M., Rose, D. W., Flynn, S. E. et al., Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation, Genes Dev., 1998, 12: 3357–3368.PubMedCrossRefGoogle Scholar
  28. 28.
    Fan, S., Wang, J., Meng, Q. et al., BRCA1 inhibits estrogen receptor signaling in transfected cells, Science, 1999, 284: 1354–1356.PubMedCrossRefGoogle Scholar
  29. 29.
    Fan, S., Wang, J., Ma, Y. X. et al., Role of direct interaction in BRCA1 inhibition of estrogen receptor activity, Oncogene, 2001, 22: 77–87.CrossRefGoogle Scholar
  30. 30.
    Fan, S., Ma, Y. X., Yuan, R. et al., P300 modulates the BRCA1 inhibition of estrogen receptor activity, Cancer Res., 2002, 62: 141–151.PubMedGoogle Scholar
  31. 31.
    Fan, S., Yuan, R., Ma, Y. X. et al., Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1, Oncogene, 2001, 20: 8215–8235.PubMedCrossRefGoogle Scholar
  32. 32.
    Benton, W. D., Davis, P. W., Screening λgt recombinant clones by hybridization to single plaques in situ, Science, 1977, 196: 180–182.PubMedCrossRefGoogle Scholar
  33. 33.
    Sanger, F., Nicklen, S., Coulson, A. R., DNA sequencing with chain termination inhibitors, Proc. Natl. Acad. Sci. USA, 1977, 74: 5463–5467.PubMedCrossRefGoogle Scholar
  34. 34.
    Fukushi, M., Dixon, J., Kimura, T. et al., Identification and cloning of a novel cellular protein Naf1, Nef-associated factor 1, that increases cell surface CD4 expression, FEBS Lett., 1999, 442: 83–88.PubMedCrossRefGoogle Scholar

Copyright information

© Science in China Press 2003

Authors and Affiliations

  • Meng Qinghui 
    • 1
  • Zhou Lixin 
    • 2
  • Cao Jianping 
    • 3
  • Gao Bin 
    • 4
  • Shao Rongguang 
    • 5
  • Li Jiyou 
    • 2
  • Fan Saijun 
    • 1
    • 2
    • 3
    • 5
  1. 1.Laboratory of Molecular OncologyNorth Shore-Long Island Jewish Research InstituteNew YorkUSA
  2. 2.Department of Pathology, Beijing Cancer HospitalPeking UniversityBeijingChina
  3. 3.School of Radiology and Public HealthSuzhou UniversitySuzhouChina
  4. 4.Division on Liver Biology, Institute of Alcohol Abuse and AlcoholismNational Institutes of HealthMarylandUSA
  5. 5.Institute of Medicinal BiotechnologyChinese Academy of Medical SciencesBeijingChina

Personalised recommendations